Credit: Tel Aviv University
A new study at Tel Aviv University found that the British variant (termed: B.1.1.7) of Covid-19 is 45% more contagious than the original virus. The researchers relied on data from about 300,000 PCR tests for Covid-19 obtained from the COVID-19 testing lab, which was established in collaboration with the Electra Group.
The new study was conducted by Prof. Ariel Munitz and Prof. Moti Gerlitz of the Department of Clinical Microbiology and Immunology at the Sackler Faculty of Medicine, together with Dr. Dan Yamin and PhD student Matan Yechezkel from the Laboratory for Epidemic Modeling and Analysis (LEMA) at the Department of Industrial Engineering, all at Tel Aviv University. The study s results were published in the prominent scientific journal
TAU Study: British Variant 45% More Contagious than Original Coronavirus | The Jewish Press - JewishPress com | Jewish Press News Desk | 8 Iyyar 5781 – April 20, 2021
jewishpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jewishpress.com Daily Mail and Mail on Sunday newspapers.
Archyde
April 20, 2021 by archyde
Thorough investigation by Tel Aviv University.
A new study by Tel Aviv University found that the British variant (B 1.1.7) of Covid-19 is 45 percent more contagious than the original virus. The researchers relied on data from around 500,000 PCR tests for Covid-19, which had been obtained from the Covid-19 test laboratory, which was set up in collaboration with the Electra Group. The new study was carried out by Ariel Munitz and Moti Geritz from the Department of Clinical Microbiology and Immunology and the Sackler Faculty of Medicine. This was done in collaboration with Dan Yamin and PhD student Matan Yechezkel from the LEMA laboratory at the Department of Industrial Technology, all at Tel Aviv University. The results of the study were published in the prominent scientific journal “Cell Reports Medicine”. The joint laboratory between Tel Aviv University and Electra was created in March 2020, right after the first wave of the pandemic broke out
The Globe and Mail Opinion
If we want to be ready for the next pandemic, Canada’s biotech industry will need to be stronger Michael Houghton and D. Lorne Tyrrell Contributed to The Globe and Mail Published April 15, 2021 Bookmark Please log in to listen to this story. Also available in French and Mandarin. Log In Create Free Account
Getting audio file . This translation has been automatically generated and has not been verified for accuracy. Full Disclaimer
Michael Holly/The Canadian Press
Michael Houghton is the director of the University of Alberta’s Li Ka Shing Applied Virology Institute and the winner, in October, of the
‘Don’t fear the blood clots or second dose’
HEALTH & SCIENCE
A medical worker prepares a dose of the AstraZeneca coronavirus disease (COVID-19) vaccine, during a mass vaccination program in Monterrey, Mexico April 12, 2021. [REUTERS/Daniel Becerril]
There is no association between the Oxford/AstraZeneca vaccine and blood clots among Kenyans who have taken the jab, as reported in other parts of the world, local medical experts have said.
Ahmed Kalebi, a consultant pathologist, said less than 50 people had reported blood clots in Kenya, compared to the millions vaccinated globally.
As such, the vaccination will continue uninterrupted.
Dr Kalebi said people developed blood clots for various reasons, including immobility, food and daily inactivity.
vimarsana © 2020. All Rights Reserved.